PARP酵素在乳腺癌療法中的作用(Nature) 太鼎生物科技有限公司(02)86609496－太鼎生物科技/太鼎食安科技

PARP酵素在乳腺癌療法中的作用(Nature)

研究發現，BRCA1/2突變細胞（它們在DNA修復的同源重組通道中是有缺陷的）對PARP酵素（參與鹼基切補修復）的抑制極為敏感。這一發現為由BRCA突變引起的婦女乳腺癌的治療找到一種新的、毒性小得多的治療方法。因為PARP抑制因數對具有功能性同源重組的細胞沒有作用，所以人們的希望是，這種新療法只針對乳腺癌細胞。通過開發PARP抑制化療方法，也許有可能研製成利用一種“合成毒藥"效應的藥物來，可以用這種藥物來代替傳統的非針對性細胞毒性抗癌療法。

PARP in vivo Pharmacodynamic Assay II

PARP catalyzes the NAD-dependent addition of poly (ADP-ribose) (PAR) onto itself and adjacent nuclear proteins. Furthermore, polymorphisms in the PARP-1 gene correspond to disease predisposition, and variation in PARP activity might have an impact on the effects of PARP inhibitors in clinical settings. To address the need to monitor PARP activity among different individuals, and within cells, Trevigen's improved validated PARP in vivo Pharmacodynamic Assay II measures net PAR levels in cellular extracts and has been used to document differences in PAR levels among tumor lysates from different tissues, organs and xenografts. The HT PARP in vivo Pharmacodynamic Assay II employs a purified, pre-coated monoclonal PAR antibody as the capture agent, and anti-PAR polyclonal rabbit antibody as the detecting agent.

PARP產品特點	· Fewer user steps · Pre-coated 96 well capture antibody plates · High signal to noise ratio · Detection sensitivity of 2 pg/ml of PAR · Broad linear dynamic range to 1,000 pg/ml · Reduced inter-assay variability · Commercially available validated assay that measures drug action on PARP in both in vivo and in vitro settings

PARP產品應用:	· Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts. · Monitoring the efficacy of PARP inhibitors on PAR formation in vivo. · Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy. · Facilitating development of PARP and PARG targeted therapeutics

Components:	Part #	Component	Size
	4520-096-01	PAR Standard, 25 pg/μl	5 x 20 μl
	4520-096-02	Sample Buffer	20 ml
	4520-096-03	PAR Polyclonal Detecting Antibody	30 μl
	4520-096-04	Goat anti-Rabbit IgG-HRP	30 μl
	4675-096-01	PARP PeroxyGlow^™ A	6 ml
	4675-096-02	PARP PeroxyGlow^™ B	6 ml
	4520-096-05	Cell Lysis Reagent	30 ml
	4520-096-06	DNase 1, 2 Units/μl	60 μl
	4520-096-07	100X Magnesium Cation	500 μl
	4520-096-P	Pre-coated white 96-stripwell plate, and 5 sealers	1 plate
	4520-096-08	Jurkat Cell Lysate Standard Control, Low	600 μl
	4520-096-09	Jurkat Cell Lysate Standard Control, Medium	600 μl
	4520-096-10	Jurkat Cell Lysate Standard Control, High	600 μl
	4520-096-11	Antibody Diluent	15 ml
	4520-096-12	20% (w/v) SDS	1 ml

Storage:	Components are stored at -80°C , -20°C , 4°C , and room temperature

References:	1. Virag, L., and Szabo, C. 2002. The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacological Reviews 54:375-429. 2. Thiemermann, C., J. Bowes, F.P. Myint, and J.R. Vane. 1997. Inhibition of the activity of poly(ADP-ribose) synthase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-83. 3. Curtin NJ. 2005. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20. 4. Kinders JK, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute Phase 0 Clinical Trials Team. 2008. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 14:6877-85.